Yeast Infection Treatment Market Outlook from 2024 to 2034

The global yeast infection treatment market was valued at USD 6158.8 million in 2023. The market is estimated to surge at a CAGR of 5.0%, reaching a valuation of USD 10031.3 million in 2034. The primary factors driving this market's expansion include the advent of novel fungal illnesses, as well as the rise in autoimmune disorders and yeast infections.

Attributes Key Insights
Anticipated Market Value (2023A) USD 6158.8 million
Estimated Yeast Infection Treatment Market Size (2024E) USD 6479.8 million
Projected Yeast Infection Treatment Market Value (2034F) USD 10031.3 million
Value-based Yeast Infection Treatment Market CAGR (2024 to 2034) 5.0%

Market expansion is projected to be fueled by the global economic recovery, which enables consumers to access better and higher-quality healthcare. Increasing patient awareness and knowledge of yeast infections is a buffer for market expansion through 2034.

Market growth is also anticipated to be fueled by government support for research and development activities in creating antifungal drugs. In addition, the market is expected to rise significantly due to the funding from the government for medical research & development and innovative therapies for yeast infections.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2019 to 2023 Global Yeast Infection Treatment Market Insights Vs. 2024 to 2034

Yeast infection treatment market sales account for around 39.4% of the share globally. The market was valued at USD 6158.8 million in 2023. The global yeast infection treatment market recorded a historic CAGR of 3.9% from 2019 to 2023.

Global yeast infection treatment market expansion is anticipated to be driven by an increasing number of yeast infection cases, particularly in women. As of 2022, around 70% of women have encountered vulvovaginal candidiasis at least once in their lives, and 8% of them have had recurrent vulvovaginal candidiasis, per NCBI studies.

Yeast infections, also known as Candida infections, have become more common worldwide. Several variables, such as weakened immune systems, broad-spectrum antibiotics, and lifestyle changes, contribute to the rising incidence of yeast infections.

Public education and awareness of yeast infections have received more attention recently. Pharmaceutical companies and healthcare providers have initiated awareness campaigns to educate the public about the symptoms and preventive actions associated with yeast infections.

Through research and development, ongoing efforts have been made to look into novel therapeutic approaches and formulations for yeast infection treatment.

Treatments for yeast infections are widely available worldwide, and access to medications and healthcare has improved for emerging economies. Population growth, urbanization, and improvements in the healthcare system are some of the factors behind this surge.

Yeast Infection Treatment Market Trends and Analysis

  • Recent Developments: Efforts are being made to develop antifungal medications that are more precise and effective. This covers advancements in medication formulations, modes of administration, and investigation of new substances to counteract resistant varieties.
  • Preventive Measures: To lower the recurrence of yeast infections, healthcare practitioners are emphasizing preventive measures. This covers lifestyle suggestions, including keeping one's body clean, abstaining from needless antibiotic use, and fostering a robust immune system.
  • Technology: How mobile applications and telehealth services are integrated into healthcare is changing the face of treating yeast infections. Through telemedicine, anyone can consult medical professionals at a distance, making diagnosis and treatment more accessible.
  • Increasing Public Awareness: Healthcare organizations and pharmaceutical corporations are actively involved in awareness initiatives to educate the public about yeast infections.
Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Factors Restraining Demand for Yeast Infection Treatment

  • Antifungal Resistance: One of the biggest obstacles to treating yeast infections is the emergence of resistance to antifungal drugs. Similar to medicines, antifungal medication abuse or overuse can hasten the evolution of resistant yeast strains.
  • Limited Drug Approvals: Developing and approving new pharmaceuticals can be expensive and time-consuming. The availability of innovative and more potent treatment options for yeast infections can be limited.
  • Cost: The price of antifungal drugs, particularly those associated with more recent and sophisticated therapies, can be a deterrent. For some, access to specific prescriptions can be restricted due to financial constraints.

Country-wise Insights

The table below highlights the anticipated growth rates of different countries. Among these, India is expected to remain a highly lucrative market for yeast infection treatment, exhibiting a CAGR of 5.8%. China and Japan are anticipated to follow with CAGRs of 5.4% and 5.7%, respectively.

Countries Projected CAGR (2024 to 2034)
United States 5.2%
China 5.4%
Germany 4.9%
India 5.8%
Japan 5.7%

Growing Prevalence of Fungal Infections in the United States to Surge Demand

The United States dominated North America’s yeast infection treatment market with a share of around 90.5% in 2022. It is expected to continue to experience the same growth rate throughout the forecast period.

Understanding population preferences is critical for pharmaceutical companies operating in the yeast infection treatment market. The United States yeast infection treatment market will likely expand due to population growth, aging population, and increasing health consciousness.

In the United States, prescription and over-the-counter antifungal drugs are frequently used to treat yeast infections. Oral antifungal treatments such as fluconazole, suppositories, and topical antifungal creams are set to be common medications in the United States.

Rising Public Knowledge of Yeast Infections in Germany to Influence Market

Candida auris poses a concern to patients in healthcare facilities across Europe, particularly in Germany, because of its potential to cause epidemics and its antifungal tolerance. Due to ongoing efforts to raise national awareness of yeast infection, prevention and control measures, the market is expected to surge in Germany.

Over-the-counter (OTC) medications, such as suppositories and antifungal lotions, give people self-treatment choices. This accessibility influences the dynamics of the market as a whole.

Germany-based healthcare groups regularly participate in awareness programs to raise public knowledge of yeast infections. This details risk factors, symptoms, and the significance of consulting a medical expert for yeast infection treatment.

Increasing Research and Development Activities in China to Fuel Growth

China reached a valuation of USD 301.7 million, withholding a significant market share of around 28.9% by 2022. China, in particular, is home to a variety of unknown yeasts that have the potential to be pathogenic in exposed hosts.

One of the key factors influencing the market for yeast infection treatment is the regulatory landscape in China, which includes the approval procedure for new medications and therapies. Market dynamics can be affected by consumer preferences for particular brands or treatment types and the rising popularity of natural or home cures.

Economic considerations can affect the population's accessibility to treatments for yeast infections, including healthcare spending, insurance coverage, and pharmaceutical prices. China continues to lead the world in the research & development of antifungal drugs, including investigating novel compounds and treatment approaches.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights

The table below signifies leading sub-categories under the route of administration, form, and distribution channel segment categories in the yeast infection treatment market. The oral segment is expected to surge at a CAGR of 5.2% in the evaluation period. Under the form category, the tablets/ capsules segment is projected to rise at a CAGR of 5.4% by 2034.

Oral to Rule over Other Rout of Administrations Available in the Market

Route of Administration Value-based CAGR
IV/IM 5.4%
Oral 5.2%

Based on the route of administration, the oral segment has driven the market by holding a significant share of around 54.6% in 2022. Due to its benefits, including non-invasiveness, patient compliance, and ease of drug administration, it is the most favored method in the market.

The oral route of administration is recommended for systemic antifungal treatment since it enables convenient and patient-friendly dosage. The drug can be taken by the patient at home, and this method of delivery is frequently preferred by the patient over intravenous therapy.

When prescribing oral antifungal drugs, healthcare providers should consider patient compliance, drug interactions, and possible side effects. Furthermore, new oral antifungal medications are being introduced into the market to treat yeast infections as a result of ongoing research and development activities.

Demand to Remain High for Tablets/Capsules Through 2034

Form Value-based CAGR
Tablets/ Capsules 5.4%
Cream / Ointments 5.0%

Based on form, the tablets/capsules segment has led the market by holding a remarkable share of 45.8% in 2022. Tablets are available in different shapes and have a longer shelf life. Also, they can withstand a higher dosage of an active chemical.

The specific antifungal medication, patient preferences, and the stability & bioavailability of the formulation are a handful of the elements that influence the demand for tablets and capsules. Tablets and capsules include benefits such as precise dosing, simplicity of storage, and enhanced patient compliance, which would drive sales.

Online Sales to Remain the Most Remunerative Distribution Channel Worldwide

Distribution Channel Value-based CAGR
Online Sales 6.0%
Retail Pharmacies/ Drug Stores 5.5%

Based on distribution channels, retail pharmacies/drug stores have driven the global market, withholding a share of around 31.2% in 2022. Working long hours, drive-through facilities, and a wide variety of prescription and over-the-counter pharmaceuticals are the key drivers boosting the demand for retail pharmacies and drug stores.

Several e-commerce sites and online pharmacies let customers buy products for treating yeast infections straight from their websites. This covers popular websites such as Walmart, Amazon, and specialized online pharmacies.

Conventional merchants frequently offer an online presence that enables customers to order items for treating yeast infections and have them delivered to their homes. This covers both big-box pharmacies and independent health and wellness stores.

Competitive Landscape

The market as a whole is fragmented due to the several players in the yeast infection treatment sector. In order to fulfill consumer demand and expand their client base, key firms are launching new products, forming partnerships & collaborations, and engaging in mergers & acquisitions.

Instances of key developmental strategies by leading players in the yeast infection treatment market are given below:

  • In May 2022, a drug called Vivjoa (oteseconazolas) received FDA approval for the treatment of both acute and chronic vaginal yeast infections.
  • In June 2021, the FDA approved a novel drug to treat vaginal yeast infections. The first in a new category of triterpenoid antifungal drugs, Brexafemme is a once-a-day oral medication made by SCYNEXIS.
  • In October 2022, Intas launched Itraconazole-SB, a novel antifungal medication. This new medication will drastically save costs and improve patient compliance.

Scope of the Report

Attribute Details
Estimated Yeast Infection Treatment Market Size (2024) USD 6479.8 million
Projected Yeast Infection Treatment Market Value (2034) USD 10031.3 million
Anticipated Growth Rate (2024 to 2034) 5.0%
Forecast Period 2024 to 2034
Historical Data Available for 2019 to 2023
Market Analysis USD million for Value
Key Regions Covered North America; Latin America; Europe; East Asia; South Asia; Oceania; and Middle East and Africa
Key Countries Covered United States, Canada, Brazil, Mexico, Argentina, Rest of Latin America, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Rest of Europe, Japan, China, South Korea, India, Thailand, Indonesia, Malaysia, Australia, New Zealand, Türkiye, GCC, South Africa, North Africa and Rest of Middle East and Africa
Key Market Segments Covered Treatment Type, Indication, Route of Administration, Form, Distribution Channel, and Region
Key Companies Profiled Astellas Pharma Inc.; Astra Zeneca; Abbott Laboratories; Allergan; Brundavan Laboratories Private Limited; Bayer; Corden Pharma; Merck & Co., Inc.; Novartis; Pfizer Inc.; Synmedic Laboratories; Sanofi

Yeast Infection Treatment Market Segmentation by Category

By Treatment Type:

  • Azoles
  • Polygene
  • Echinocandin
  • Others

By Indication:

  • Genital Candidiasis
  • Invasive Candidiasis
  • Oropharyngeal/Esophageal Candidiasis (Thrush)
  • Others

By Route of Administration:

  • Oral
  • Topical
  • IV/IM
  • Others

By Form:

  • Powders
  • Creams/Ointments
  • Tablets/Capsules
  • Others

By Distribution Channel:

  • Retail Pharmacies/Drug Stores
  • Hospital Pharmacies
  • Specialty Stores
  • Online Sales
  • Others (Hypermarkets/ Conventional Stores)

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • Middle-East and Africa

Frequently Asked Questions

How big is the yeast infection treatment industry?

The yeast infection treatment market size is estimated to reach USD 6158.8 million in 2023.

What is the expected size of the yeast infection treatment market in 2034?

The target market size is expected to reach USD 10031.3 million in 2034.

What are the trends driving demand in the market?

The emergence of new fungal infections and increasing use of antibiotics would fuel growth.

Who are the key manufacturers in the yeast infection treatment market?

Astellas Pharma Inc., Astra Zeneca, and Abbott Laboratories are the leading players.

What was the CAGR of the yeast infection treatment market from 2019 to 2023?

The market for yeast infection treatment expanded at a CAGR of 3.9%.

What is the demand outlook for yeast infection treatment?

Yeast infection treatment demand is set to surge at a 5.0% CAGR through 2034.

Table of Content
  • 1. Executive Summary
  • 2. Market Overview
  • 3. Key Market Trends
  • 4. Key Success Factors
  • 5. Market Background
  • 6. Global Market Demand (in Value USD million) Analysis 2019 to 2023 and Forecast, 2024 to 2034
  • 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Treatment Type
    • 7.1. Azoles
    • 7.2. Polygene
    • 7.3. Echinocandin
    • 7.4. Others
  • 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Indication
    • 8.1. Genital Candidiasis
    • 8.2. Invasive Candidiasis
    • 8.3. Oropharyngeal/Esophageal Candidiasis (Thrush)
    • 8.4. Others
  • 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Route of Administration
    • 9.1. Oral
    • 9.2. Topical
    • 9.3. IV/IM
    • 9.4. Other
  • 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Form
    • 10.1. Powders
    • 10.2. Creams/Ointments
    • 10.3. Tablets/Capsules
    • 10.4. Others
  • 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Distribution Channel
    • 11.1. Retail Pharmacies/Drug Stores
    • 11.2. Hospital Pharmacies
    • 11.3. Specialty Stores
    • 11.4. Online Sales
    • 11.5. Others (Hypermarkets/Conventional Stores)
  • 12. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region
    • 12.1. North America
    • 12.2. Latin America
    • 12.3. Europe
    • 12.4. East Asia
    • 12.5. South Asia
    • 12.6. Oceania
    • 12.7. Middle East and Africa
  • 13. North America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
  • 14. Latin America Market Analysis 2019 to 2023 and Forecast 2024 to 2034
  • 15. Europe Market Analysis 2019 to 2023 and Forecast 2024 to 2034
  • 16. East Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034
  • 17. South Asia Market Analysis 2019 to 2023 and Forecast 2024 to 2034
  • 18. Oceania Market 2019 to 2023 and Forecast 2024 to 2034
  • 19. Middle East and Africa (MEA) Market Analysis 2019 to 2023 and Forecast 2024 to 2034
  • 20. Market Structure Analysis
  • 21. Competition Analysis
    • 21.1. Abbott Laboratories
    • 21.2. Astellas Pharma Inc.
    • 21.3. Astra Zeneca
    • 21.4. Allergan
    • 21.5. Brundavan Laboratories Private Limited
    • 21.6. Bayer
    • 21.7. Corden Pharma
    • 21.8. Merck & Co., Inc.
    • 21.9. Novartis
    • 21.10. Pfizer Inc.
    • 21.11. Synmedic Laboratories
    • 21.12. Sanofi
  • 22. Assumptions and Acronyms Used
  • 23. Research Methodology
Recommendations

Healthcare

Yeast Infection Diagnostics Market

July 2023

REP-GB-17572

250 pages

Healthcare

Venous Ulcer Treatment Market

February 2023

REP-GB-16620

289 pages

Healthcare

Eye Infections Treatment Market

July 2022

REP-GB-1300

256 pages

Explore Healthcare Insights

View Reports
Future Market Insights

Yeast Infection Treatment Market

Schedule a Call